Clinical Trials Logo
  1. Home
  2. Panic Disorder
  3. NCT00038896
  4. Details
NCT00038896 Clinical Trial

Study Evaluating Venlafaxine ER in Adults With Panic Disorder

Panic Disorder Clinical Trial

Official title:
A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00038896
Other study ID # 0600B5-353
Secondary ID
Status Completed
Phase Phase 3
First received June 5, 2002
Last updated August 13, 2009
Start date April 2001
Est. completion date December 2002

Study information
Verified date August 2009
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

Recruitment information / eligibility
Status Completed
Enrollment 343
Est. completion date December 2002
Est. primary completion date December 2002
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- A male or female outpatient

- Be at least 18 years of age and legal age of consent

- Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1

Exclusion Criteria:

- Treatment with venlafaxine (IR or ER) within 6 months of study day 1

- Known hypersensitivity to venlafaxine (IR or ER) or related compounds

- History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal cell epithelioma], uncontrolled hypertension)

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Venlafaxine ER

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer
See also
  Status Clinical Trial Phase
Recruiting NCT05868135 - Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT02998502 - The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens N/A
Completed NCT01955954 - Using the Canary Breathing System for Panic Disorder Patients N/A
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00605813 - Special Investigation Of Long Term Use Of Sertraline.
Completed NCT00353470 - Comparison of Psychotherapy Programs to Treat Panic Disorder Phase 3
Completed NCT00167479 - A Study of Risperidone Monotherapy in Bipolar Anxiety Phase 4
Completed NCT00540098 - Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Phase 4
Completed NCT03233542 - The Association Between Physical Sensations and Thinking Styles N/A
Recruiting NCT05967468 - Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT04592536 - A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects Phase 1
Completed NCT00025974 - Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT01680107 - D-cycloserine Augmented CBT for Panic Disorder Phase 3